The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Rivastigmine Oral Market Research Report 2024

Global Rivastigmine Oral Market Research Report 2024

Publishing Date : Jan, 2024

License Type :
 

Report Code : 1804476

No of Pages : 91

Synopsis
Rivastigmine (sold under the trade name Exelon) is a acetylcholinesterase inhibitor used for the treatment of mild to moderate Alzheimer's disease and Parkinson's. The drug can be administered orally or via a transdermal patch; the latter form reduces the prevalence of side effects, which typically include nausea and vomiting.
The global Rivastigmine Oral market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Rivastigmine Oral is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Rivastigmine Oral is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Rivastigmine Oral include Novartis, Sun Pharmaceutical, Mylan Pharmaceuticals, Teva, Dr. Reddy's Laboratories, Orchid Healthcare, APOTEX, Alembic Pharmaceuticals and MACLEODS, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Rivastigmine Oral, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Rivastigmine Oral.
Report Scope
The Rivastigmine Oral market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Rivastigmine Oral market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Rivastigmine Oral manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis
Sun Pharmaceutical
Mylan Pharmaceuticals
Teva
Dr. Reddy's Laboratories
Orchid Healthcare
APOTEX
Alembic Pharmaceuticals
MACLEODS
Cadila Pharmaceuticals
Aurobindo Pharma
Ajanta Pharma
Segment by Type
1.5 mg Capsules
3 mg Capsules
4.5 mg Capsules
6 mg Capsules
2mg/ml Oral Solution
Segment by Application
Alzheimer's Disease
Parkinson's Disease
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Rivastigmine Oral manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Rivastigmine Oral in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index
1 Rivastigmine Oral Market Overview
1.1 Product Overview and Scope of Rivastigmine Oral
1.2 Rivastigmine Oral Segment by Type
1.2.1 Global Rivastigmine Oral Market Value Comparison by Type (2024-2030)
1.2.2 1.5 mg Capsules
1.2.3 3 mg Capsules
1.2.4 4.5 mg Capsules
1.2.5 6 mg Capsules
1.2.6 2mg/ml Oral Solution
1.3 Rivastigmine Oral Segment by Application
1.3.1 Global Rivastigmine Oral Market Value by Application: (2024-2030)
1.3.2 Alzheimer's Disease
1.3.3 Parkinson's Disease
1.4 Global Rivastigmine Oral Market Size Estimates and Forecasts
1.4.1 Global Rivastigmine Oral Revenue 2019-2030
1.4.2 Global Rivastigmine Oral Sales 2019-2030
1.4.3 Global Rivastigmine Oral Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Rivastigmine Oral Market Competition by Manufacturers
2.1 Global Rivastigmine Oral Sales Market Share by Manufacturers (2019-2024)
2.2 Global Rivastigmine Oral Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Rivastigmine Oral Average Price by Manufacturers (2019-2024)
2.4 Global Rivastigmine Oral Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Rivastigmine Oral, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Rivastigmine Oral, Product Type & Application
2.7 Rivastigmine Oral Market Competitive Situation and Trends
2.7.1 Rivastigmine Oral Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Rivastigmine Oral Players Market Share by Revenue
2.7.3 Global Rivastigmine Oral Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Rivastigmine Oral Retrospective Market Scenario by Region
3.1 Global Rivastigmine Oral Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Rivastigmine Oral Global Rivastigmine Oral Sales by Region: 2019-2030
3.2.1 Global Rivastigmine Oral Sales by Region: 2019-2024
3.2.2 Global Rivastigmine Oral Sales by Region: 2025-2030
3.3 Global Rivastigmine Oral Global Rivastigmine Oral Revenue by Region: 2019-2030
3.3.1 Global Rivastigmine Oral Revenue by Region: 2019-2024
3.3.2 Global Rivastigmine Oral Revenue by Region: 2025-2030
3.4 North America Rivastigmine Oral Market Facts & Figures by Country
3.4.1 North America Rivastigmine Oral Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Rivastigmine Oral Sales by Country (2019-2030)
3.4.3 North America Rivastigmine Oral Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Rivastigmine Oral Market Facts & Figures by Country
3.5.1 Europe Rivastigmine Oral Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Rivastigmine Oral Sales by Country (2019-2030)
3.5.3 Europe Rivastigmine Oral Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Rivastigmine Oral Market Facts & Figures by Country
3.6.1 Asia Pacific Rivastigmine Oral Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Rivastigmine Oral Sales by Country (2019-2030)
3.6.3 Asia Pacific Rivastigmine Oral Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Rivastigmine Oral Market Facts & Figures by Country
3.7.1 Latin America Rivastigmine Oral Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Rivastigmine Oral Sales by Country (2019-2030)
3.7.3 Latin America Rivastigmine Oral Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Rivastigmine Oral Market Facts & Figures by Country
3.8.1 Middle East and Africa Rivastigmine Oral Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Rivastigmine Oral Sales by Country (2019-2030)
3.8.3 Middle East and Africa Rivastigmine Oral Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Rivastigmine Oral Sales by Type (2019-2030)
4.1.1 Global Rivastigmine Oral Sales by Type (2019-2024)
4.1.2 Global Rivastigmine Oral Sales by Type (2025-2030)
4.1.3 Global Rivastigmine Oral Sales Market Share by Type (2019-2030)
4.2 Global Rivastigmine Oral Revenue by Type (2019-2030)
4.2.1 Global Rivastigmine Oral Revenue by Type (2019-2024)
4.2.2 Global Rivastigmine Oral Revenue by Type (2025-2030)
4.2.3 Global Rivastigmine Oral Revenue Market Share by Type (2019-2030)
4.3 Global Rivastigmine Oral Price by Type (2019-2030)
5 Segment by Application
5.1 Global Rivastigmine Oral Sales by Application (2019-2030)
5.1.1 Global Rivastigmine Oral Sales by Application (2019-2024)
5.1.2 Global Rivastigmine Oral Sales by Application (2025-2030)
5.1.3 Global Rivastigmine Oral Sales Market Share by Application (2019-2030)
5.2 Global Rivastigmine Oral Revenue by Application (2019-2030)
5.2.1 Global Rivastigmine Oral Revenue by Application (2019-2024)
5.2.2 Global Rivastigmine Oral Revenue by Application (2025-2030)
5.2.3 Global Rivastigmine Oral Revenue Market Share by Application (2019-2030)
5.3 Global Rivastigmine Oral Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Novartis
6.1.1 Novartis Corporation Information
6.1.2 Novartis Description and Business Overview
6.1.3 Novartis Rivastigmine Oral Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Novartis Rivastigmine Oral Product Portfolio
6.1.5 Novartis Recent Developments/Updates
6.2 Sun Pharmaceutical
6.2.1 Sun Pharmaceutical Corporation Information
6.2.2 Sun Pharmaceutical Description and Business Overview
6.2.3 Sun Pharmaceutical Rivastigmine Oral Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Sun Pharmaceutical Rivastigmine Oral Product Portfolio
6.2.5 Sun Pharmaceutical Recent Developments/Updates
6.3 Mylan Pharmaceuticals
6.3.1 Mylan Pharmaceuticals Corporation Information
6.3.2 Mylan Pharmaceuticals Description and Business Overview
6.3.3 Mylan Pharmaceuticals Rivastigmine Oral Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Mylan Pharmaceuticals Rivastigmine Oral Product Portfolio
6.3.5 Mylan Pharmaceuticals Recent Developments/Updates
6.4 Teva
6.4.1 Teva Corporation Information
6.4.2 Teva Description and Business Overview
6.4.3 Teva Rivastigmine Oral Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Teva Rivastigmine Oral Product Portfolio
6.4.5 Teva Recent Developments/Updates
6.5 Dr. Reddy's Laboratories
6.5.1 Dr. Reddy's Laboratories Corporation Information
6.5.2 Dr. Reddy's Laboratories Description and Business Overview
6.5.3 Dr. Reddy's Laboratories Rivastigmine Oral Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Dr. Reddy's Laboratories Rivastigmine Oral Product Portfolio
6.5.5 Dr. Reddy's Laboratories Recent Developments/Updates
6.6 Orchid Healthcare
6.6.1 Orchid Healthcare Corporation Information
6.6.2 Orchid Healthcare Description and Business Overview
6.6.3 Orchid Healthcare Rivastigmine Oral Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Orchid Healthcare Rivastigmine Oral Product Portfolio
6.6.5 Orchid Healthcare Recent Developments/Updates
6.7 APOTEX
6.6.1 APOTEX Corporation Information
6.6.2 APOTEX Description and Business Overview
6.6.3 APOTEX Rivastigmine Oral Sales, Revenue and Gross Margin (2019-2024)
6.4.4 APOTEX Rivastigmine Oral Product Portfolio
6.7.5 APOTEX Recent Developments/Updates
6.8 Alembic Pharmaceuticals
6.8.1 Alembic Pharmaceuticals Corporation Information
6.8.2 Alembic Pharmaceuticals Description and Business Overview
6.8.3 Alembic Pharmaceuticals Rivastigmine Oral Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Alembic Pharmaceuticals Rivastigmine Oral Product Portfolio
6.8.5 Alembic Pharmaceuticals Recent Developments/Updates
6.9 MACLEODS
6.9.1 MACLEODS Corporation Information
6.9.2 MACLEODS Description and Business Overview
6.9.3 MACLEODS Rivastigmine Oral Sales, Revenue and Gross Margin (2019-2024)
6.9.4 MACLEODS Rivastigmine Oral Product Portfolio
6.9.5 MACLEODS Recent Developments/Updates
6.10 Cadila Pharmaceuticals
6.10.1 Cadila Pharmaceuticals Corporation Information
6.10.2 Cadila Pharmaceuticals Description and Business Overview
6.10.3 Cadila Pharmaceuticals Rivastigmine Oral Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Cadila Pharmaceuticals Rivastigmine Oral Product Portfolio
6.10.5 Cadila Pharmaceuticals Recent Developments/Updates
6.11 Aurobindo Pharma
6.11.1 Aurobindo Pharma Corporation Information
6.11.2 Aurobindo Pharma Rivastigmine Oral Description and Business Overview
6.11.3 Aurobindo Pharma Rivastigmine Oral Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Aurobindo Pharma Rivastigmine Oral Product Portfolio
6.11.5 Aurobindo Pharma Recent Developments/Updates
6.12 Ajanta Pharma
6.12.1 Ajanta Pharma Corporation Information
6.12.2 Ajanta Pharma Rivastigmine Oral Description and Business Overview
6.12.3 Ajanta Pharma Rivastigmine Oral Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Ajanta Pharma Rivastigmine Oral Product Portfolio
6.12.5 Ajanta Pharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Rivastigmine Oral Industry Chain Analysis
7.2 Rivastigmine Oral Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Rivastigmine Oral Production Mode & Process
7.4 Rivastigmine Oral Sales and Marketing
7.4.1 Rivastigmine Oral Sales Channels
7.4.2 Rivastigmine Oral Distributors
7.5 Rivastigmine Oral Customers
8 Rivastigmine Oral Market Dynamics
8.1 Rivastigmine Oral Industry Trends
8.2 Rivastigmine Oral Market Drivers
8.3 Rivastigmine Oral Market Challenges
8.4 Rivastigmine Oral Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Published By : QY Research

Why ‘The Market Reports’